Loading clinical trials...
Loading clinical trials...
Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine (VCIV) to Prevent Culture Confirmed Influenza Infection (CCII)
Conditions
Interventions
Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)
Phosphate buffered saline
Locations
34
United States
Tucson, Arizona, United States
Anaheim, California, United States
Sacramento, California, United States
San Diego, California, United States
San Francisco, California, United States
Clearwater, Florida, United States
Start Date
November 1, 2007
Primary Completion Date
June 1, 2008
Completion Date
June 1, 2008
Last Updated
October 17, 2023
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
Alachua Government Services, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions